



Review

Journey of cystatins from being mere thiol protease inhibitors to at heart of many pathological conditions



Anas Shamsi, Bilqees Bano*

Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, 202002, India

ARTICLE INFO

Article history:

Received 21 March 2017

Received in revised form 18 April 2017

Accepted 19 April 2017

Available online 23 April 2017

Keywords:

Cystatins

Cancer

Kidney

ABSTRACT

Cystatins are thiol proteinase inhibitors (TPI), present ubiquitously in animals, plants and micro-organisms. These are not merely inhibitors rather they are at heart of many pathological conditions ranging from diabetes to renal failure. These are essential for maintenance of protein balance of the cell; once this balance gets disturbed, it may lead to cell death. Thus, cystatins cannot be merely regarded as TPI's as these have been found to play a pivotal role in tumorigenesis and neurodegenerative diseases. Many studies have reported the variation in cystatin level in incidences of different types of cancer; highlighting an important role played by these inhibitors in cancer development and progression. Cystatin C is increasingly replacing creatinine as a biomarker of glomerular filtration rate (GFR) thereby highlighting the importance of this important inhibitor. Some recent studies have also reported the interaction pattern of various anti-cancer drugs with cystatins in a bid to find how these drugs affect this important inhibitors and whether these drugs have any side effect on cystatins. Thus, in this growing disease era it can be said that cystatins are no more just inhibitors blocking the activity of thiol proteases rather they play a pivotal role in variety of pathological conditions.

© 2017 Elsevier B.V. All rights reserved.

Contents

1. General.....	675
1.1. Proteases.....	675
1.2. Cysteine proteases.....	676
1.3. Mammalian cysteine proteases.....	676
1.3.1. Cathepsins.....	676
1.3.2. Caplains.....	676
1.3.3. Caspases.....	677
1.3.4. Legumains.....	678
2. Cystatins.....	678
2.1. Cystatin superfamily.....	678
2.2. Stefin family (TYPE I CYSTATINS).....	678
2.2.1. Stefin A (Cystatin A or α).....	679
2.2.2. Stefin B (cystatin B).....	679
2.2.3. Stefin C.....	679
2.3. Cystatin family (type 2 cystatins).....	679
2.3.1. Cystatin C.....	680
2.3.2. Cystatin D.....	680
2.3.3. Cystatin F.....	680
2.3.4. Cystatin E/M.....	681
2.3.5. Cystatin S.....	681

* Corresponding author.

E-mail address: bbano17@gmail.com (B. Bano).

2.4.	Kininogens family (type 3 cystatins)	681
2.5.	Phycocystatin family (type 4 cystatins)	682
2.6.	Othet cystatins and cystatin-like proteases	682
3.	Cysteine protease-cystatin interaction	682
4.	Role of cystatins in various diseases	683
4.1.	Cystatins in cancer and tumor immune response	683
4.2.	Type II cystatins in pathological processes	683
4.3.	Role of cystatins in neurodegenerative diseases	683
5.	Structure of cystatins	685
5.1.	Primary structure	685
5.2.	Secondary structure	685
6.	Emerging properties of cystatins	686
6.1.	Stabilization of matrix metalloproteinases by cystatins	686
6.2.	Role of cystatin C as a new marker of glomerular filtration rate	686
6.3.	Immunomodulatory properties of cystatins	686
6.4.	Kinetic analysis	686
7.	Kidney	686
7.1.	Kidney structure	686
7.2.	Different kidney conditions	687
7.2.1.	Pyelonephritis (infection of kidney pelvis)	687
7.2.2.	Glomerulonephritis	687
7.2.3.	Kidney stones (nephrolithiasis)	687
7.2.4.	Nephrotic syndrome	687
7.2.5.	Polycystic kidney disease	687
7.2.6.	Acute renal failure (kidney failure)	687
7.2.7.	Chronic renal failure	687
7.2.8.	End stage renal disease (ESRD)	688
7.2.9.	Papillary necrosis	688
7.2.10.	Diabetic nephropathy	688
7.2.11.	Hypertensive nephropathy	688
7.2.12.	Kidney cancer	688
7.2.13.	Interstitial nephritis	688
7.2.14.	Minimal change disease	688
7.2.15.	Nephrogenic diabetes insipidus	688
7.2.16.	Renal cyst	688
7.3.	Different kidney tests	688
7.3.1.	Urinalysis	688
7.3.2.	Kidney ultrasound	688
7.3.3.	Computed tomography (CT scan)	688
7.3.4.	Magnetic resonance imaging (MRI scan)	688
7.3.5.	Urine and blood cultures	688
7.3.6.	Ureteroscopy	688
7.3.7.	Kidney biopsy	688
7.4.	Different kidney treatments	688
7.4.1.	Antibiotics	688
7.4.2.	Nephrostomy	688
7.4.3.	Lithotripsy	688
7.4.4.	Nephrectomy	688
7.4.5.	Dialysis	688
7.4.6.	Hemodialysis	688
7.4.7.	Peritoneal dialysis	688
7.4.8.	Kidney transplant	688
8.	Fates of protein during folding process: overview of protein folding study	688
8.1.	Transition/intermediate states in protein folding	689
8.2.	Protein misfolding and aggregation	689
8.3.	Different types of aggregates	689
8.4.	Amyloid states results from protein abnormalities	689
8.5.	Toxic species in aggregation	689
9.	Conclusion	690
	Conflict of interest	690
	References	690

1. General

1.1. Proteases

Proteases are enzymes that irreversibly hydrolyze a peptide bond in an amino acid sequence by nucleophilic attack. Traditionally, proteases were thought of as digestive enzymes that cleave

proteins into smaller peptides and amino acids and their role was thought of as merely being involved in turnover of cellular proteins or digestion of nutrient proteins. In recent times, this perception has evolved and proteases are now seen as vital signaling molecules that are involved in variety of processes. Protease signaling pathways are strictly regulated; any dysregulation of protease activity can lead to pathologies such as cardiovascular and inflammatory

Download English Version:

<https://daneshyari.com/en/article/5511795>

Download Persian Version:

<https://daneshyari.com/article/5511795>

[Daneshyari.com](https://daneshyari.com)